<DOC>
	<DOCNO>NCT00003731</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness temozolomide treat patient recurrent oligodendroglial tumor .</brief_summary>
	<brief_title>Temozolomide Treating Patients With Recurrent Oligodendroglial Tumors</brief_title>
	<detailed_description>OBJECTIVES : I. Assess therapeutic activity temozolomide first line chemotherapy patient recurrent oligodendroglial tumor radiation therapy . II . Assess objective response duration response patient give treatment . III . Characterize acute side effect temozolomide patient population . OUTLINE : This open label , multicenter study . Patients receive oral temozolomide day 1-5 . Courses repeat every 28 day . Treatment continue maximum 12 course absence unacceptable toxicity disease progression . Patients follow every 3 month disease progression . PROJECTED ACCRUAL : A total 15-33 patient accrue study .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven oligodendroglioma oligoastrocytoma least 25 % oligodendroglial element Recurrent progressive disease follow radiotherapy At least 3 month since prior radiotherapy Measurable disease MRI CT scan Lesion must diameter least 1 cm No progressive neurological deficit present recurrence No new neurological deficit interfere daily activity No tumor cause midline shift brain stem compression due rapid deterioration expect case response No sign increase intracranial pressure No extracranial disease PATIENT CHARACTERISTICS : Age : 18 70 Performance status : WHO 02 Life expectancy : At least 3 month Hematopoietic : Neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.25 time upper limit normal ( ULN ) AST/ALT great 2 time ULN Alkaline phosphatase great 2 time ULN Renal : Creatinine clearance least 60 mL/min Creatinine great 1.25 time ULN Neurologic : See Disease Characteristics Other : Not pregnant nursing Fertile patient must use effective contraception No malignant nonmalignant diseases interfere followup No psychological , familial , sociological , geographical condition potentially hamper compliance study followup PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Surgery : Not specify Other : No concurrent investigational drug No concurrent antitumor agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
</DOC>